Merck sets $54K list price for hep C combo as it preps for battle with Gilead, AbbVie

Carly Helfand Industry watchers have long been speculating on how Merck would take on heavyweights Gilead and AbbVie when it priced its new hep C regimen. And now, they have their answer: ...

Gilead faces legal action in Massachusetts if it doesn’t cut hep C prices: State AG

Tracy Staton Gilead Sciences is facing more hepatitis C pushback from state officials. The Massachusetts attorney general is warning that it will take legal action against the California-based ...

Yes, Gilead put superhigh prices on hep C drugs, but what can you do? Senators ask

Eric Palmer After 18 months spent slicing and dicing 20,000 pages of Gilead Sciences documents and emails, a Senate investigation concluded that the drugmaker put very high price tags ...

What can Gilead, Biogen and Celgene teach Big Pharma about R&D?

John Carroll For the past 5 years the biopharma experts at Deloitte have been keeping an eye on a disturbing trend that shows no sign of letting up anytime soon. The biggest players ...

Gilead takes a $125M FDA shortcut with its latest HIV combo

Damian Garde Last year, Gilead Sciences paid $ 125 million for a ticket promising a speedy FDA review. Now the Big Biotech is cashing it in, submitting a combination HIV treatment ...

Gilead jumps into epigenetics with a bite-size biotech buyout

Damian Garde As market watchers wonder whether Gilead Sciences is on the verge of a blockbuster buyout, the Big Biotech inked a small deal that will beef up its efforts in the growing ...

Who’s the new king of the drug launch hill? Hint: It’s all in the Gilead family

Tracy Staton Move over, Sovaldi–there's a new launch king in town. And luckily for Gilead, it's another of its own. Harvoni has officially unseated its hep C ...

Gilead strikes Sovaldi price deal in Germany as it picks up speed in EU

Eric Palmer Just days after Gilead COO John Milligan told investors to expect negotiations for its hep C franchise to unfold very quickly in Europe, Germany has said it has a deal to ...

Gilead, AbbVie rack up new payer deals, but hep C obstacles loom across the Atlantic

Tracy Staton The hepatitis C market is breaking new ground all over the place. As payers put the squeeze on Gilead Sciences and AbbVie for discounts in the U.S., England's National ...

Shire chief: We want to be like Gilead, Biogen and Celgene

Damian Garde On the rebound after a dalliance with AbbVie and its $ 55 billion red herring, Shire CEO Flemming Ornskov is back on the offensive, talking up his company's potential ...

Orphan drug prices on non-orphan meds? Gilead, this means you, PBM says

Tracy Staton Anyone following the hepatitis C drug market knows that Express Scripts CMO Steve Miller has a strong point of view. FiercePharma News

Gilead misses the mark in Q3 due to Obamacare fee and dip in Sovaldi revenue

Emily Wasserman Gilead Sciences is charting eye-popping sales for blockbuster Sovaldi and chalking up a key regulatory approval for its new hep C combo pill, Harvoni. But the company's ...
© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS